Search

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found